Trial Profile
Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Octohydroaminoacridine succinate (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 11 Oct 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Oct 2019).
- 20 Oct 2019 Planned End Date changed from 16 Feb 2020 to 16 Feb 2021.
- 20 Oct 2019 Planned primary completion date changed from 16 Sep 2019 to 16 Sep 2020.